NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

After October 13, 2022, this dataset will no longer be updated as the related CDC COVID Data Tracker site was retired on October 13, 2022.

This dataset contains historical trends in vaccinations and cases by age group, at the US national level. Data is stratified by at least one dose and fully vaccinated. Data also represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

The VICP program publishes a summary PDF report with several data tables: Number of Petitions Filed by Adjudication Categories by Alleged Vaccine, including # of doses distributed (2006-2014) Number of Petitions Filed, Compensated, and Dismissed by Alleged Vaccine (cumulative 1998 through 2016) Number of Petitions Filed by year (1998-2017) Number of Adjudications compensable, dismissed and total (FY1989 - FY2017) Awards paid including amounts, attorneys fees, and total outlays (FY1989 - FY2016)

Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

This table will no longer be updated after 5/30/2024 given the end of the 2023-2024 viral respiratory vaccine season.

This table shows the cumulative number and percentage of CT residents who have received an updated COVID-19 vaccine during the 2023-2024 viral respiratory season by age group (current age).
CDC recommends that people get at least one dose of this vaccine to protect against serious illness, whether or not they have had a COVID-19 vaccination before. Children and people with moderate to severe immunosuppression might be recommended more than one dose. For more information on COVID-19 vaccination recommendations, click here.
• Data are reported weekly on Thursday and include doses administered to Saturday of the previous week (Sunday – Saturday). All data in this report are preliminary. Data from the previous week may be changed because of delays in reporting, deduplication, or correction of errors.
• These analyses are based on data reported to CT WiZ which is the immunization information system for CT. CT providers are required by law to report all doses of vaccine administered. CT WiZ also receives records on CT residents vaccinated in other jurisdictions and by federal entities which share data with CT Wiz electronically. Electronic data exchange is being added jurisdiction-by-jurisdiction. Currently, this includes Rhode Island and New York City but not Massachusetts and New York State. Therefore, doses administered to CT residents in neighboring towns in Massachusetts and New York State will not be included. A full list of the jurisdiction with which CT has established electronic data exchange can be seen at the bottom of this page (https://portal.ct.gov/immunization/Knowledge-Base/Articles/Vaccine-Providers/CT-WiZ-for-Vaccine-Providers-and-Training/Query-and-Response-functionality-in-CT-WiZ?language=en_US)
• Population size estimates used to calculate cumulative percentages are based on 2020 DPH provisional census estimates*.
• People are included if they have an active jurisdictional status in CT WiZ at the time weekly data are pulled. This excludes people who live out of state, are deceased and a small percentage who have opted out of CT WiZ.
* DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Using a Danish register-based study on childhood vaccination and hospitalisation as motivation, a marginal structural model for recurrent events is studied. The model addresses a number of challenges which may be seen more generally in large register-based cohort studies. One is to adjust for a time-dependent confounder when studying the effect of a time-varying exposure on a recurrent event based on an analysis in continuous time. Another is to report results via a measure which is easy to interpret and communicate even though quite elaborate treatment regimes are considered. Lastly, the implementation of continuously updated weights implies a substantial computationally demanding workload.

Percentages of children and pregnant women who have received recommended vaccines, by target population and vaccine/antigen covering results from the 2011, 2013, 2015, 2017, 2019, and 2021 cycles of the Childhood National Immunization Coverage Survey.

BY: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 97.000 % in 2023. This records a decrease from the previous number of 98.000 % for 2022. BY: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 98.000 % from Dec 1992 (Median) to 2023, with 32 observations. The data reached an all-time high of 99.000 % in 2015 and a record low of 93.000 % in 1995. BY: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Belarus – Table BY.World Bank.WDI: Social: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.;WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).;Weighted average;

CA: Immunization: HepB3: % of One-Year-Old Children data was reported at 83.000 % in 2023. This stayed constant from the previous number of 83.000 % for 2022. CA: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 69.000 % from Dec 2003 (Median) to 2023, with 21 observations. The data reached an all-time high of 84.000 % in 2021 and a record low of 14.000 % in 2007. CA: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Canada – Table CA.World Bank.WDI: Social: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.;WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).;Weighted average;

Human Papilloma Virus (HPV) is a preventable cause of cervical cancer, the most common cancer among women in Uganda. The Uganda Ministry of Health included the HPV vaccine in the free routine immunization schedule since 2015. Five years after this policy, we assessed the uptake of the HPV vaccine and associated socio-demographic factors among young women living in fishing communities in Central Uganda in 2020. We analyzed secondary data from 94 young women aged 9–25 years who were recruited from the two fishing communities (Kasenyi landing site and Koome Island) in a primary implementation study that aimed to promote awareness of maternal and childhood vaccines. We assessed uptake of the HPV vaccine as the proportion of participants who self-reported to have ever received at least one dose of the HPV vaccine. We assessed the socio-demographic factors associated with HPV vaccine uptake using a modified Poisson regression model adjusted for clustering by study site in STATA version 17. Th..., This was a secondary analysis of data collected from a larger implementation project that aimed at increasing awareness of maternal vaccines in fishing communities of Wakiso and Mukono districts in Uganda. This data was extracted from the main datasets by the data manager, no identifying infromation was included. Data analysis was done in STATA version 17.0 (Texas USA)., , # Uptake of Human Papilloma Virus Vaccine among young women in fishing communities in Wakiso and Mukono districts, Uganda

This dataset is a STATA file (created in STATA version 17.0). It contains all the variables used in the analysis that gave rise to the findings reported in this Manuscript. Variable descriptions and the value labels are provided in the file.

Description of the data and file structure

The data are in the form of a STATA file with an extension of "dta". It can be opened in STATA software. The value for each variable is already defined with the respective value labels and also the variable descriptions are in this dataset

Sharing/Access information

Some variables in the data like actual age, religion, tribe and number of children were not included in this data set to preserve confidentiality. However, data on these variables can be accessed by contacting the corresponding author

Data can also be accessed by contacting the corresponding author at

STATA C...

Context

There's a story behind every dataset and here's your opportunity to share yours.

Content

What's inside is more than just rows and columns. Make it easy for others to get started by describing how you acquired the data and what time period it represents, too.

Acknowledgements

We wouldn't be here without the help of others. If you owe any attributions or thanks, include them here along with any citations of past research.

Inspiration

Your data will be in front of the world's largest data science community. What questions do you want to see answered?

CDC46 - Employees aged 18 years and over who have received a vaccine. Published by Central Statistics Office. Available under the license Creative Commons Attribution 4.0 (CC-BY-4.0).Employees aged 18 years and over who have received a vaccine...

This table presents a series of indicators relating to the COVID-19 pandemic, including relating to perceptions of Canadians' mental health, precautions they've taken, and willingness to receive vaccine. Estimates are based on preliminary monthly data from the Canadian Community Health Survey, and are provided for the Canadian population aged 12 and older excluding the territories, by gender, age and region of residence.

Context

To be honest it's pretty hard for you to find data on vaccine progress and especially time-based data on a country like Pakistan. So, I created this small but interactive notebook that will keep updating the database until everyone is vaccinated. In this project I have used Pandas for easy WebSracping to get the data from pharmaceutical-technology.com then I have created Sqlite3 database to store the data into three tables. It took me a few tries to get everything working smooth so I started using SQL queries to get the data and then used plotly to plot interactive visualization. I was not sure when they will update the website so, I have created few functions to avoid duplication of data and to inform me on telegram about updates. I have also uploaded the processed data to Kaggle from Deepnote which will be updated daily. At last, I have used the Deepnote Schedule notebook feature to run this notebook every day and successfully publishing the article You can find my work on Deepnote.

Content

• World_Vaccination_Progress.csv -> Countries Vaccination progress
• pakistan_time_series.csv -> Time series data of Pakistan vaccine progress
• world_time_series.csv -> Time series data of World vaccine progress

Columns: - Country :: Names of countries in the world - Doses Administered: Total Doses Administered - Doses per 1000 : Number of Doses per thousand - Fully Vaccinated Population (%) : Percentage of a fully vaccinated person in a country. - Vaccine being used in a country : Types of vaccines used in a country.

For Time-Series

• Date_Time : Timestamp of entry

Acknowledgements

I am thankful for Pharmaceutical Technology for updating the stats on daily basis and publicly provide real-time stats of world's vaccination drive. I also want to thank Deepnote for the introduction of the Schedule notebook feature that has made this automation possible.

Inspiration

The lack of data available in my country drove me to create an automated system that collects data from web. You can read more about it in my article. The second inspiration came from participating in Deepnote competition which was on the data Vaccination drive of your country or World.